The molecular diagnostics firm said in an amended prospectus that it plans to offer 1.3 million shares of its common stock at between $6.35 and $6.75 per share.
The multi-analyte Zika virus assay was developed by a Luminex partner, GenArraytion, and is available now for research use only.
The isothermal technology from Cascade Biosystems performs about as well as qPCR and could be used in niche DNA detection applications.
The money from the Massachusetts Life Sciences Center will go toward developing a test that does not require laboratory instrumentation.
NEW YORK (GenomeWeb) – Nanosphere today reported a 38 percent jump in its first quarter revenues, but fell short of the consensus Wall Street estimates on the top and bottom lines.
NEW YORK (GenomeWeb News) – Invetech will support the development and manufacture of Biocartis' multiplex platform for biomarker analysis under an agreement announced today.
NEW YORK (GenomeWeb News) – Axela today announced a development deal to integrate Thermal Gradient's rapid PCR technology into Axela's Flow-Thru Chip automated workflow.
NEW YORK (GenomeWeb News) – Trovagene said in a regulatory filing today that it has entered into a deal with Illumina to evaluate the possible integration of Trovagene's transrenal technology with Illumina's sequencing technology.
NEW YORK (GenomeWeb News) – EnviroLogix today announced an agreement with Douglas Scientific to develop and optimize solutions for high-throughput real-time and endpoint nucleic acid analysis.
Enzymatics received ISO standards certification for manufacturing its proteins that are used for research and diagnostics purposes with a focus on nucleic acid detection technologies.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.